Reuters logo
BRIEF-Akebia Therapeutics provides update on Janssen deal
February 13, 2017 / 12:28 PM / 7 months ago

BRIEF-Akebia Therapeutics provides update on Janssen deal

Feb 13 (Reuters) - Akebia Therapeutics Inc :

* Akebia Therapeutics - Janssen could be eligible to receive up to aggregate of $16.5 million from co in specified development milestone payments

* Akebia Therapeutics - Janssen to be eligible to receive up to $215 million from co in specified commercial milestones as well as tiered, escalating royalties

* Akebia Therapeutics - unless earlier terminated, deal will expire on a product-by-product and country-by-country basis upon expiration of last royalty term

* Akebia Therapeutics-co may terminate deal in its entirety or only with respect to particular licensed compound upon 180 days' prior written notice to Janssen Source text: (bit.ly/2lbdICf) Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below